Trial · NCT01034631
Adverse events840
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 840
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ACIDOSIS (METABOLIC OR RESPIRATORY) | Metabolism and nutrition disorders | Phase I Participants | 1 | 15 | 1 |
| other | ACIDOSIS (METABOLIC OR RESPIRATORY) | Metabolism and nutrition disorders | Phase II: Arm A | 1 | 70 | 1 |
| other | ACIDOSIS (METABOLIC OR RESPIRATORY) | Metabolism and nutrition disorders | Phase II: Arm B Participants | 0 | 69 | 0 |
| other | ALBUMIN, SERUM-LOW (HYPOALBUMINEMIA) | Investigations | Phase I Participants | 2 | 15 | 3 |
| other | ALBUMIN, SERUM-LOW (HYPOALBUMINEMIA) | Investigations | Phase II: Arm A | 7 | 70 | 11 |
| other | ALBUMIN, SERUM-LOW (HYPOALBUMINEMIA) | Investigations | Phase II: Arm B Participants | 7 | 69 | 8 |
| other | ALKALINE PHOSPHATASE | Investigations | Phase I Participants | 5 | 15 | 6 |
| other | ALKALINE PHOSPHATASE | Investigations | Phase II: Arm A | 10 | 70 | 14 |
| other | ALKALINE PHOSPHATASE | Investigations | Phase II: Arm B Participants | 14 | 69 | 19 |
| other | ALLERGIC REACTION/HYPERSENSITIVITY (INCLUDING DRUG FEVER) | Immune system disorders | Phase I Participants | 1 | 15 | 3 |
| other | ALLERGIC REACTION/HYPERSENSITIVITY (INCLUDING DRUG FEVER) | Immune system disorders | Phase II: Arm A | 2 | 70 | 5 |
| other | ALLERGIC REACTION/HYPERSENSITIVITY (INCLUDING DRUG FEVER) | Immune system disorders | Phase II: Arm B Participants | 2 | 69 | 2 |
| other | ALLERGIC RHINITIS (INCLUDING SNEEZING, NASAL STUFFINESS, POSTNASAL DRIP) | Immune system disorders | Phase I Participants | 4 | 15 | 4 |
| other | ALLERGIC RHINITIS (INCLUDING SNEEZING, NASAL STUFFINESS, POSTNASAL DRIP) | Immune system disorders | Phase II: Arm A | 4 | 70 | 4 |
| other | ALLERGIC RHINITIS (INCLUDING SNEEZING, NASAL STUFFINESS, POSTNASAL DRIP) | Immune system disorders | Phase II: Arm B Participants | 7 | 69 | 7 |
| other | ALLERGY/IMMUNOLOGY | Immune system disorders | Phase I Participants | 4 | 15 | 5 |
| other | ALLERGY/IMMUNOLOGY | Immune system disorders | Phase II: Arm A | 0 | 70 | 0 |
| other | ALLERGY/IMMUNOLOGY | Immune system disorders | Phase II: Arm B Participants | 5 | 69 | 6 |
| other | ALT, SGPT (SERUM GLUTAMIC PYRUVIC TRANSAMINASE) | Investigations | Phase I Participants | 1 | 15 | 2 |
| other | ALT, SGPT (SERUM GLUTAMIC PYRUVIC TRANSAMINASE) | Investigations | Phase II: Arm A | 8 | 70 | 14 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01034631/events